A novel complement therapeutic CTx001 offers a novel approach to treating geographic atrophy. Complement Therapeutics (CTx) is a Germany-based preclinical stage biotechnology company focusing on the R ...

Alexion has announced a collaboration with Dicerna Pharmaceuticals to discover and develop RNA interference therapies for diseases caused by problems in the complement system. Boston-based Alexion ...

Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...

Most people infected with the SARS-CoV-2 virus recover after the acute illness. However, a significant proportion of infected individuals develop long-lasting symptoms with a wide range of ...

Changes to serum proteins could be behind the debilitating condition known as long COVID. The findings, published in the journal Science, could pave the way for diagnosing and treating the disease.

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

The "Dense Deposit Disease Market - A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region - Analysis and Forecast, 2025-2035" has been added to ...

A preclinical biotechnology company, spun out of The University of Manchester, has announced the completion of a €72 million finance deal to develop the treatment of a leading cause of blindness. The ...

Round led by Gimv, a Belgian based private equity and venture capital firm Round comes just 1 year after raising €5 million seed funding in February 2022 Company aims to transform the treatment of ...